Record overview
Status and phase
Status: TERMINATED
Phase: PHASE1, PHASE2
Sponsor: Oncopeptides AB
Condition: Multiple Myeloma
NCT03481556
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Registry Stop Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
The sponsor decided to terminate the study following an FDA request of a partial clinical hold.